Race towards a Successful Intervention for Covid-19 {#s0005}
===================================================

Over the past two decades, three novel pathogenic human coronaviruses have emerged from animal reservoirs \[[@bb0005]\]. These are Middle East respiratory syndrome-related coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), and, most recently, severe acute respiratory syndrome coronavirus 2 (referred to as COVID-19, SARS-CoV-2, or 2019-nCoV). All three have led to global health emergencies, with significant morbidity and mortality \[[@bb0010]\]. Before 2020, the largest outbreak was of SARS-CoV in 2003, which affected over 8000 individuals globally and was associated with 774 deaths (case fatality rate of 9.6%)[i](#p0125){ref-type="p"} \[[@bb0015]\]. The overall cost to the global economy of SARS-CoV was estimated to be between US\$30 billion and US\$100 billion \[[@bb0020]\].

Following the first identification in patients with severe pneumonia in Wuhan province, China in November 2019, COVID-19 has spread rapidly and now affects all permanently inhabited continents. This is the greatest pandemic of modern times and has been declared a Public Health Emergency of International Concern by the WHO Director-General[ii](#p0130){ref-type="p"}. As of 27 March 2020 (date of submission), COVID-19 was affecting 199 countries and territories, with \>510 000 confirmed cases globally[iii](#p0135){ref-type="p"}. It is associated with an estimated mortality of between 1% and 5%[iii](#p0135){ref-type="p"}. Furthermore, human-to-human transmission has continued apace, despite escalating public health measures. Current estimates of the impact on the worldwide economy are US\$1 trillion and rising[iv](#p0140){ref-type="p"}.

Currently, there are no approved therapies for either the treatment or prevention of COVID-19. With the predicted number of cases set to rise significantly, this represents a prodigious acute unmet medical need. Several national and international research groups are working collaboratively on a variety of preventative and therapeutic interventions. Potential avenues being explored include vaccine development, convalescent plasma, interferon-based therapies, small-molecule drugs, cell-based therapies, and monoclonal antibodies (mAbs) \[[@bb0025]\]. However, drug therapy development is a costly and timely process with a high attrition rate \[[@bb0030]\]. The speed of the normal drug development pathway is unacceptable in the context of the current global emergency. Therefore, there has been considerable interest in repurposing existing drugs and expediting developmental antiviral treatments, such as those for influenza, hepatitis B (HBV), hepatitis C (HCV), and filoviruses, to allow more rapid development \[[@bb0025]\]. The swift genomic sequencing of COVID-19 has facilitated this process, allowing comparison with MERS-CoV, SARS-CoV, and other morbific viruses \[[@bb0035]\]. This strategy has identified several genomic regions of interest for therapeutic modulation, specifically the identification of highly conserved regions involving viral enzymes between different pathogenic coronaviruses.

Exploring Current Clinical Trials for Covid-19 {#s0010}
==============================================

Since 2005, it has been recommended by the International Committee of Medical Journal Editors (ICMJE) that all clinical trials should be registered in publicly available domains before they may be considered for publication \[[@bb0040]\]. The introduction of this requirement and other initiatives to increase clinical trial transparency has contributed to an increasing number of trials being recorded in online registries, such as ClinicalTrials.gov[v](#p0145){ref-type="p"} and the International Clinical Trials Registry Platform (ICTRP)[vi](#p0150){ref-type="p"} of the WHO. The logging of trials on registries has vastly facilitated the dissemination of information across several domains, including intervention, methodology, patient group, and outcome measures. Furthermore, in the event of the nonpublication of results, it means that trial information remains freely available for analysis.

In the context of the current global COVID-19 pandemic, we performed an analysis of online registries (ClinicalTrials.gov[v](#p0145){ref-type="p"}, WHO ICTRP[vi](#p0150){ref-type="p"}, EU Clinical Trials Register[vii](#p0155){ref-type="p"}, and Cochrane Central Register of Controlled Trials[viii](#p0160){ref-type="p"}; [Figure 1](#f0005){ref-type="fig"} ) to collate all registered therapeutic and preventative interventions under clinical investigation. We hope that this will clarify current investigational advances and guide potential future strategies. We identified 344 interventional studies focusing on both preventative strategies and the treatment of patients with COVID-19 ([Figure 1](#f0005){ref-type="fig"}) as of 20 March 2020. This search identified 100 studies that focused on forms of traditional Chinese medicine (TCM), including herbal medicines, acupuncture and other forms of complementary medicine. These have not been further analysed due to a lack of scientific rationale, inadequate provision of information regarding active ingredients, and limited applicability to mainstream medical practice. [Table 1](#t0005){ref-type="table"} (Key Table) shows interventional treatments ([Table 1](#t0005){ref-type="table"}A) and preventative strategies ([Table 1](#t0005){ref-type="table"}B) under clinical investigation for COVID-19.Figure 1Flow Diagram Showing the Study Selection Process of Clinical Trials Discussed in This Article and Listed in [Table 1](#t0005){ref-type="table"} in the Main Text.Data in the WHO International Clinical Trials Registry were incorporated from various national registries, including those from Australia, New Zealand, China, The Netherlands, Brazil, India, Cuba, Republic of Korea, Germany, Iran, Japan, Sri Lanka, Thailand, and Peru, and also [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0005}, EU Clinical Trials registry, International Standard Randomised Controlled Trial Number (ISRCTN)[xi](#p0175){ref-type="p"}, and the Pan-African registries. Three studies included treatment for patients with COVID-19 and an intervention to prevention infection in uninfected patients.Figure 1Table 1Key Table. Ongoing Clinical Trials for the (A) Treatment and (B) Prevention of COVID-19 (Current as of 20 March, 2020)[a](#tf0005){ref-type="table-fn"}Table 1Clinical trial ID (Registry)Intervention[b](#tf0010){ref-type="table-fn"}Size[c](#tf0015){ref-type="table-fn"}RandomisedBlindedStatusCountry of origin (pharma sponsor)**(A) Ongoing clinical trials for treatment of COVID-19Antiviral**ChiCTR2000029609 (ICTPR)**Arm A** (mild--moderate): chloroquine\
**Arm B** (mild--moderate): lopinavir/ritonavir\
**Arm C** (mild--moderate): lopinavir/ritonavir + chloroquine\
**Arm D** (severe): lopinavir/ritonavir\
**Arm E** (severe): chloroquine205NoNoRecruitingChinaChiCTR2000029600 (ICTPR)**Arm A:** interferon alpha atomisation\
**Arm B** lopinavir/ritonavir and interferon alpha atomisation\
**Arm C:** favipiravir and interferon alpha atomisation90NoNoRecruitingChinaNCT04261270 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0015})**Arm A: ASC09** and **oseltamivir**\
**Arm B:** ritonavir and oseltamivir\
**Arm C:** oseltamivir60YesSingleRecruitingChinaNCT04261907 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0020})**Arm A:** ASC09/ritonavir\
**Arm B:** lopinavir/ritonavir160YesNoRecruitingChina (Ascletis Pharm)ChiCTR2000030487 (ICTPR)**Arm A:** azvudine10NoNoRecruitingChinaChiCTR2000030424 (ICTPR)**Arm A:** azvudine30NoNoNot recruitingChinaChiCTR2000030041 (ICTPR)**Arm A:** azvudine40NoNoNot recruitingChinaChiCTR2000029853 (ICTPR)**Arm A:** azvudine\
**Arm B:** standard treatment20YesNoRecruitingChinaChiCTR2000029544 (ICTPR)**Arm A:** baloxavir marboxil\
**Arm B:** favipiravir\
**Arm C:** standard treatment30YesUnspecifiedNot recruitingChinaChiCTR2000029548 (ICTPR)**Arm A:** baloxavir marboxil\
**Arm B:** favipiravir\
**Arm C:** lopinavir/ritonavir30YesNoNot recruitingChinaChiCTR2000030001 (ICTPR)**Arm A:** basic treatment + triazavirin\
**Arm B:** basic treatment240YesYesRecruitingChinaNCT04273763 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0025})**Arm A:** bromhexine (mucolytic), umifenovir, interferon a2b, and favipiravir\
**Arm B:** umifenovir and interferon a2b60YesNoRecruitingChina (WanBangDe Pharm. Group)ChiCTR2000030002 (ICTPR)**Arm A:** conventional treatment\
**Arm B:** conventional treatment + **tranilast**60YesNoRecruitingChinaChiCTR2000030472 (ICTPR)**Arm A:** danoprevir/ritonavir\
**Arm B:** standard treatment20UnspecifiedNoRecruitingChinaChiCTR2000030259 (ICTPR)**Arm A:** danoprevir/ritonavir\
**Arm B:** standard treatment60YesUnspecifiedRecruitingChinaChiCTR2000030000 (ICTPR)**Arm A:** danoprevir/ritonavir\
**Arm B: Pegasys**\
**Arm C: Novaferon**\
**Arm D:** Coriolus\
**Arm E:** standard treatment50UnspecifiedNoRecruitingChinaNCT04252274 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0030})**Arm A:** darunavir and cobicistat\
**Arm B:** standard treatment30YesNoRecruitingChinaNCT04304053 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0035})**Arm A:** darunavir/cobicistat\
**Arm B:** isolation3040YesNoRecruitingSpainChiCTR2000029541 (ICTPR)**Arm A:** darunavir/cobicistat and **thymosin**\
**Arm B:** lopinavir/ritonavir and thymosin\
**Arm C:** thymosin100YesNoNot recruitingChinaNCT04291729 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0040})**Arm A:** darunavir/ritonavir and atomised interferon\
**Arm B:** peginterferon a2\
**Arm C:** interferon alpha (Novaferon)\
**Arm D:** lopinavir/ritonavir\
**Arm E:** atomised interferon + Chinese medicine (unspecified)50NoNoRecruitingChina (Ascletis Pharmaceutical)ChiCTR2000030535 (ICTPR)**Arm A: ebastine** and **interferon** alpha inhalation and lopinavir\
**Arm B:** interferon alpha inhalation and lopinavir100YesSingleRecruitingChinaChiCTR2000030113 (ICTPR)**Arm A:** favipiravir\
**Arm B:** ritonavir20YesNoRecruitingChinaChiCTR2000030254 (ICTPR)**Arm A:** favipiravir\
**Arm B:** umifenovir240YesNoRecruitingChinaChiCTR2000030987 (ICTPR)**Arm A:** favipiravir and chloroquine\
**Arm B:** favipiravir\
**Arm C:** placebo150YesUnspecifiedRecruitingChinaNCT04310228 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0045})**Arm A:** favipiravir and tocilizumab\
**Arm B:** favipiravir\
**Arm C:** tocilizumab150YesNoRecruitingChinaChiCTR2000029895 (ICTPR)**Arm A: GD31**160NoUnspecifiedRecruitingChinaIRCT20100228003449N27 (ICTPR)**Arm A:** hydroxychloroquine, lopinavir/ritonavir, and **interferon beta** 1b\
**Arm B:** hydroxychloroquine and lopinavir/ritonavir30YesNoRecruitingIranIRCT20100228003449N28 (ICTPR)**Arm A:** hydroxychloroquine, lopinavir/ritonavir, and interferon beta 1a\
**Arm B:** hydroxychloroquine and lopinavir/ritonavir30YesNoRecruitingIranIRCT20100228003449N29 (ICTPR)**Arm A:** hydroxychloroquine, lopinavir/ritonavir, and sofosbuvir/ledipasvir\
**Arm B:** hydroxychloroquine and lopinavir/ritonavir50YesNoRecruitingIranJPRN-jRCTs041190120 (ICTPR)**Arm A:** immediate favipiravir (Day 1--10)\
**Arm B:** delayed favipiravir (Day 6--15)86YesNoRecruitingJapan2020-001023-14 (EU-CTR)**Arm A:** inhaled interferon alpha 1b\
**Arm B:** placebo400YesDoubleRecruitingUK (Synairgen Ltd)ChiCTR2000029989 (ICTPR)**Arm A:** interferon a1b eye drops\
**Arm B:** placebo eye drops300YesUnspecifiedNot recruitingChinaNCT04293887 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0050})**Arm A:** interferon a1b nebulised\
**Arm B:** standard treatment328YesNoNot recruitingChinaChiCTR2000030922 (ICTPR)**Arm A:** interferon alpha 2a and **ribavirin**\
**Arm B:** umifenovir and ribavirin30YesUnspecifiedRecruitingChinaChiCTR2000029308 (ICTPR) \[[@bb0055]\]**Arm A:** lopinavir/ritonavir\
**Arm B** standard treatment160YesNoRecruitingChinaNCT04307693 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0055})**Arm A:** lopinavir/ritonavir\
**Arm B:** hydroxychloroquine\
**Arm C:** no intervention150YesNoRecruitingSouth KoreaChiCTR2000030187 (ICTPR)**Arm A:** lopinavir/ritonavir\
**Arm B:** standard of care60YesUnspecifiedRecruitingChina2020-001113-21 (EU-CTR)**Arm A:** lopinavir/ritonavir\
**Arm B:** dexamethasone\
**Arm C:** interferon beta 1a\
**Arm D:** placebo2000YesNoRecruitingUK2020-000936-23 (EU-CTR)**Arm A:** lopinavir/ritonavir\
**Arm B:** interferon beta 1a\
**Arm C:** remdesivir3000YesNoRecruitingFranceNCT04251871 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0060})**Arm A:** lopinavir/ritonavir and interferon alpha inhalation and traditional Chinese medicine\
**Arm B:** lopinavir/ritonavir and interferon alpha inhalation150YesNoRecruitingChinaChiCTR2000029468 (ICTPR)**Arm A:** lopinavir/ritonavir and emtricitabine/tenofovir\
**Arm B:** lopinavir/ritonavir120UnspecifiedUnspecifiedNot recruitingChinaJPRN-jRCTs031190227 (ICTPR)**Arm A:** lopinavir/ritonavir and hydroxychloroquine50UnspecifiedUnspecifiedNot recruitingJapanChiCTR2000030166 (ICTPR)**Arm A:** lopinavir/ritonavir and interferon alpha 2b and Qing-Wen Bai-Du-Yin granules\
**Arm B:** lopinavir/ritonavir and interferon alpha 2b20YesNoNot recruitingChinaChiCTR2000030218 (ICTPR)**Arm A:** lopinavir/ritonavir and Xiyanping injection\
**Arm B:** ritonavir80UnspecifiedUnspecifiedRecruitingChinaNCT04252885 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0065})**Arm A:** lopinavir/ritonavir + basic treatment (unspecified)\
**Arm B:** umifenovir + basic treatment (unspecified)\
**Arm C:** basic treatment (unspecified)125YesNoRecruitingChinaNCT04276688 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0070})**Arm A:** lopinavir/ritonavir + ribavirin + interferon beta 1b\
**Arm B:** lopinavir/ritonavir70YesNoRecruitingHong KongChiCTR2000029539 (ICTPR)**Arm A:** lopinavir/ritonavir\
**Arm B:** standard treatment328YesNoRecruitingChinaChiCTR2000029996 (ICTPR)**Arm A:** low-dose favipiravir\
**Arm B:** medium-dose favipiravir\
**Arm C:** high-dose favipiravir60YesNoRecruitingChinaChiCTR2000029638 (ICTPR)**Arm A:** nebulised rSIFN-co\
**Arm B:** nebulised interferon alpha100YesYesRecruitingChinaChiCTR2000029496 (ICTPR)**Arm A:** Novaferon atomisation inhalation\
**Arm B:** lopinavir/ritonavir\
**Arm C:** Novaferon and lopinavir/ritonavir90YesNoRecruitingChinaNCT04303299 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0075})**Arm A:** oseltamivir and chloroquine\
**Arm B:** lopinavir/ritonavir and favipiravir\
**Arm C:** lopinavir/ritonavir and oseltamivir\
**Arm D:** lopinavir/ritonavir and oseltamivir\
**Arm E:** favipiravir and lopinavir/ritonavir\
**Arm F:** darunavir/ritonavir, oseltamivir, and chloroquine\
**Arm G:** standard treatment80YesNoNot recruitingThailandNCT04302766 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0080})**Arm A:** remdesivirUnspecifiedUnspecifiedUnspecifiedAvailableUSANCT04292899 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0085})**Arm A:** remdesivir\
**Arm B:** standard treatment400YesNoRecruitingUSA and Asia (Gilead)NCT04292730 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0090})**Arm A:** remdesivir\
**Arm B:** standard treatment600YesNoRecruitingUSA and Asia (Gilead)NCT04280705 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0095})**Arm A:** remdesivir\
**Arm B:** placebo394YesDoubleRecruitingUSA and South Korea2020-000841-15 (EU-CTR)**Arm A:** remdesivir\
**Arm B:** standard treatment400YesNoRecruitingWorldwide (Gilead)2020-000842-32 (EU-CTR)**Arm A:** remdesivir\
**Arm B:** standard treatment600YesNoRecruitingWorldwide (Gilead)NCT04252664 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0100})**Arm A:** remdesivir\
**Arm B:** placebo308YesQuadrupleRecruitingChinaNCT04257656 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0105})**Arm A:** remdesivir\
**Arm B:** placebo453YesQuadrupleRecruitingChinaNCT04315948 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0110})**Arm A:** remdesivir\
**Arm B:** lopinavir/ritonavir\
**Arm C:** lopinavir/ritonavir and interferon beta 1a\
**Arm D:** hydroxychloroquine\
**Arm E:** standard treatment3100YesNoRecruitingFranceChiCTR2000029387 (ICTPR)**Arm A:** ribavirin and interferon alpha-1b\
**Arm B:** lopinavir/ritonavir, and interferon alpha-1b\
**Arm C:** ribavirin, lopinavir/ritonavir, and interferon alpha-1b108UnspecifiedUnspecifiedRecruitingChinaIRCT20200128046294N2 (ICTPR)**Arm A: sofosbuvir/daclatasvir**\
**Arm B:** standard treatment70YesSingleRecruitingIranChiCTR2000029400 (ICTPR)**Arm A:** traditional Chinese medicine\
**Arm B:** lopinavir/ritonavir\
**Arm C:** traditional Chinese medicine and lopinavir/ritonavir60UnspecifiedUnspecifiedRecruitingChinaChiCTR2000030262 (ICTPR)**Arm A:** type 1 interferon and TFF2 dose 1\
**Arm B:** type 1 interferon and TFF2 dose 2\
**Arm C:** standard treatment30YesUnspecifiedRecruitingChinaChiCTR2000029573 (ICTPR)**Arm A:** umifenovir\
**Arm B:** Novaferon and umifenovir\
**Arm C:** lopinavir/ritonavir\
**Arm D:** umifenovir\
**Arm E:** novaferon and lopinavir/ritonavir\
**Arm F:** novaferon and umifenovir480YesNoNot recruitingChinaChiCTR2000029621 (ICTPR)**Arm A:** umifenovir\
**Arm B:** standard treatment380YesNoRecruitingChinaNCT04254874 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0115})**Arm A:** umifenovir\
**Arm B:** umifenovir and pegylated interferon alpha 2b100YesSingleRecruitingChinaNCT04255017 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0120})**Arm A:** umifenovir\
**Arm B:** oseltamivir\
**Arm C:** lopinavir/ritonavir400YesSingleRecruitingChinaChiCTR2000029993 (ICTPR)**Arm A:** umifenovir and Liushen capsule\
**Arm B:** standard treatment40YesNoRecruitingChinaNCT04275388 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0125})**Arm A:** Xiyanping injection, lopinavir/ritonavir and interferon alpha nebulisation\
**Arm B:** lopinavir/ritonavir and interfer\
n alpha nebulisation348YesNoNot recruitingChina (Jiangxi Qingfeng Pharmaceutical)**Antimalarial**ChiCTR2000030031 (ICTPR)**Arm A:** chloroquine\
**Arm B:** placebo120YesDoubleRecruitingChinaChiCTR2000029988 (ICTPR)**Arm A:** chloroquine\
**Arm B:** standard treatment80UnspecifiedUnspecifiedRecruitingChinaChiCTR2000029975 (ICTPR)**Arm A:** chloroquine10NoUnspecifiedNot recruitingChinaChiCTR2000029939 (ICTPR)**Arm A:** chloroquine\
**Arm B:** standard treatment100YesSingleRecruitingChinaChiCTR2000029935 (ICTPR)**Arm A:** chloroquine100NoUnspecifiedRecruitingChinaChiCTR2000029837 (ICTPR)**Arm A:** chloroquine\
**Arm B:** placebo120YesDoubleNot recruitingChinaChiCTR2000029826 (ICTPR)**Arm A:** chloroquine\
**Arm B:** placebo45YesDoubleNot recruitingChinaChiCTR2000029542 (ICTPR)**Arm A:** chloroquine\
**Arm B:** standard treatment20UnspecifiedUnspecifiedRecruitingChinaChiCTR2000029741 (ICTPR)**Arm A:** chloroquine\
**Arm B:** lopinavir/ritonavir112YesNoRecruitingChinaChiCTR2000030718 (ICTPR)**Arm A:** chloroquine\
**Arm B:** standard treatment80YesNoRecruitingChinaChiCTR2000029992 (ICTPR)**Arm A:** chloroquine and hydroxychloroquine\
**Arm B:** standard treatment100YesNoNot recruitingChinaChiCTR2000030417 (ICTPR)**Arm A:** chloroquine aerosol inhalation\
**Arm B** water aerosol inhalation30UnspecifiedUnspecifiedNot recruitingChinaChiCTR2000030082 (ICTPR)**Arm A: dihydroartemisinin/piperaquine** tablets combined with antiviral treatment (presumed alpha-interferon + umifenovir)\
**Arm B:** alpha-interferon + umifenovir40YesNoSuspendedChinaChiCTR2000029898 (ICTPR)**Arm A:** hydroxychloroquine\
**Arm B:** chloroquine100YesNoRecruitingChinaNCT04261517 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0130})**Arm A:** hydroxychloroquine\
**Arm B:** standard of care30YesNoRecruitingChinaChiCTR2000030054 (ICTPR)**Arm A:** hydroxychloroquine\
**Arm B:** standard treatment100YesNoNot recruitingChinaChiCTR2000029868 (ICTPR)**Arm A:** hydroxychloroquine\
**Arm B:** standard treatment200YesUnspecified.RecruitingChinaChiCTR2000029740 (ICTPR)**Arm A:** hydroxychloroquine\
**Arm B:** standard treatment78YesNoRecruitingChinaChiCTR2000029559 (ICTPR)**Arm A:** hydroxychloroquine\
**Arm B:** hydroxychloroquine\
**Arm C:** placebo300UnspecifiedUnspecifiedRecruitingChina2020-000890-25 (EU-CTR) \[[@bb0085]\]**Arm A:** hydroxychloroquine25NoNoRecruitingFranceChiCTR2000029899 (ICTPR)**Arm A:** hydroxychloroquine\
**Arm B:** chloroquine100YesNoRecruitingChinaNCT04315896 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0135})**Arm A:** hydroxychloroquine\
**Arm B:** placebo500YesQuadrupleNot recruitingMexicoNCT04316377 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0140})**Arm A:** hydroxychloroquine\
**Arm B:** standard treatment202YesNoNot recruitingNorway**Immunosuppressants**NCT04263402 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0145})**Arm A:** methylprednisolone (\<40 mg/day)\
**Arm B:** methylprednisolone (40--80 mg/day)100YesSingleRecruitingChinaChiCTR2000030089 (ICTPR)**Arm A:** conventional treatment + adalimumab\
**Arm B:** conventional treatment60YesNoNot yet recruitingChinaChiCTR2000030481 (ICTPR)**Arm A:** early corticosteroid intervention\
**Arm B:** middle--late corticosteroid intervention\
**Arm C:** standard care200YesNoRecruitingChinaNCT04288713 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0150})**Arm A:** eculizumabUnspecifiedUnspecifiedUnspecifiedAvailableUSANCT04280588 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0155})**Arm A:** fingolimod\
**Arm B:** standard treatment30NoNoRecruitingChinaChiCTR2000030703 (ICTPR)**Arm A:** ixekizumab and antiviral therapy\
**Arm B:** antiviral therapy40YesSingleRecruitingChinaNCT04275245 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0160}) \[[@bb0100]\]**Arm A:** meplazumab20NoNoRecruitingChinaNCT04273321 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0165})**Arm A:** methylprednisolone\
**Arm B:** standard treatment400YesNoRecruitingChinaNCT04244591 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0170})**Arm A:** methylprednisolone\
**Arm B:** standard treatment80YesNoRecruitingChinaChiCTR2000029656 (ICTPR)**Arm A:** methylprednisolone\
**Arm B:** standard treatment100YesNoNot recruitingChinaChiCTR2000029386 (ICTPR)**Arm A:** methylprednisolone\
**Arm B:** standard treatment48YesUnspecifiedRecruitingChinaNCT04315298 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0175})**Arm A:** sarilumab high dose\
**Arm B:** sarilumab low dose\
**Arm C:** placebo400YesQuadrupleRecruitingUSA (Regeneron Pharmaceuticals)ChiCTR2000030058 (ICTPR)**Arm A:** standard treatment + **leflunomide**\
**Arm B:** standard treatment + placebo200YesYesNot yet recruitingChinaChiCTR2000030196 (ICTPR)**Arm A:** tocilizumab60NoNoNot recruitingChinaChiCTR2000029765 (ICTPR)**Arm A:** tocilizumab\
**Arm B:** standard treatment188YesUnspecifiedRecruitingChinaNCT04315480 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0180})**Arm A:** tocilizumab30NoNoNot recruitingFranceNCT04317092 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0185})**Arm A:** tocilizumab330NoNoRecruitingItalyChiCTR2000030442 (ICTPR)**Arm A:** tocilizumab, IVIG, and CCRT100NoUnspecifiedNot recruitingChinaChiCTR2000030580 (ICTPR)**Arm A:** tozumab[d](#tf0020){ref-type="table-fn"} and adalimumab\
**Arm B:** standard treatment60YesUnspecifiedRecruitingChina**Immune modulators**NCT04317040 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0190})**Arm A:** CD24Fc\
**Arm B:** placebo230YesQuadrupleNot recruitingUSA (OncoImmune)ChiCTR2000029776 (ICTPR)**Arm A:** conventional treatment + **polyinosinic-polycytidylic acid**\
**Arm B:** conventional treatment40YesNoRecruitingChinaNCT04299724 (ICTPR)**Arm A:** Covid-19/aAPC vaccine100NoNoRecruitingChinaChiCTR2000030939 (ICTPR)**Arm A:** CSA000110YesUnspecifiedRecruitingChinaChiCTR2000030016 (ICTPR)**Arm A:** inhaled inactive *Mycobacterium* vaccine\
**Arm B:** inhaled physiological saline60YesYesRecruitingChinaChiCTR2000030167 (ICTPR)**Arm A:** interleukin-2\
**Arm B:** standard treatment80YesUnspecifiedNot recruitingChinaNCT04261426 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0195})**Arm A:** IVIG\
**Arm B:** standard treatment80YesNoNot recruitingChinaNCT04276896 (ICTPR)**Arm A:** LV-SMENP-DC vaccine and antigen specific cytotoxic T cells100NoNoRecruitingChinaNCT04268537 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0200})**Arm A:** PD-1-blocking Ab\
**Arm B:** thymosin\
**Arm C:** standard treatment120YesSingleNot recruitingChinaChiCTR2000030028 (ICTPR)**Arm A:** PD-1 mAb + standard treatment\
**Arm B:** standard treatment40YesNoNot yet recruitingChinaNCT04312997 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0205})**Arm A: PUL-042** nebuliser\
**Arm B:** sterile saline inhaler100YesQuadrupleNot recruitingUSA (Pulmotect)ChiCTR2000030750 (ICTPR)**Arm A:** recombinant chimeric DC vaccine\
**Arm B:** normal saline120YesUnspecifiedNot recruitingChinaChiCTR2000030007 (ICTPR)**Arm A:** standard treatment + rhG-CSF\
**Arm B:** standard treatment200YesNoNot yet recruitingChinaChiCTR2000029636 (ICTPR)**Arm A:** standard treatment and vMIP atomised inhalation40NoNoRecruitingChinaChiCTR2000029806 (ICTPR)**Arm A:** subcutaneous thymosin\
**Arm B:** camrelizumab infusion\
**Arm C:** conventional treatment120YesNoRecruitingChinaChiCTR2000030779 (ICTPR)**Arm A: ulinastatin** (trypsin inhibitor)\
**Arm B:** standard treatment100YesNoRecruitingChina**Cytokine removal**ChiCTR2000030475 (ICTPR)**Arm A:** CytoSorb cytokine removal19NoNoNot recruitingChinaChiCTR2000030477 (ICTPR)**Arm A:** oXiris membrane19NoNoNot recruitingChinaChiCTR2000030265 (ICTPR)**Arm A:** oXiris membrane\
**Arm B:** standard treatment30UnspecifiedUnspecifiedNot recruitingChinaChiCTR2000030835 (ICTPR)**Arm A:** high-dose MSCs\
**Arm B:** low-dose MSCs20NoUnspecifiedRecruitingChinaChiCTR2000029817 (ICTPR)**Arm A:** high-dose NK cells and MSCs\
**Arm B:** conventional-dose NK cells and MSCs\
**Arm C:** preventive-dose NK cells and MSCs60UnspecifiedUnspecifiedNot recruitingChina (Guangchou Reborn Health Management Co)ChiCTR2000029606 (ICTPR)**Arm A:** menstrual blood-derived stem cells\
**Arm B:** artificial liver therapy\
**Arm C:** artificial liver therapy and menstrual blood-derived stem cells\
**Arm D:** standard treatment73UnspecifiedUnspecifiedRecruitingChinaNCT04315987 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0210})**Arm A:** MSCs24NoNoNot recruitingBrazil (Cellavita Pesquisa Cientifica Ltd)NCT04276987 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0215})**Arm A:** MSC-derived exosomes30NoNoNot recruitingChina (Cellular Biomedicine Group)NCT04288102 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0220})**Arm A:** MSCs\
**Arm B:** placebo60YesQuadrupleRecruitingChinaNCT04252118 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0225})**Arm A:** MSCs\
**Arm B:** standard treatment20NoNoRecruitingChina (IPM, Vcanbio Cell and Gene Engineering)ChiCTR2000030300 (ICTPR)**Arm A:** MSCs9NoUnspecifiedRecruitingChinaChiCTR2000030224 (ICTPR)**Arm A:** MSCs\
**Arm B:** normal saline32UnspecifiedUnspecifiedNot recruitingChinaChiCTR2000030173 (ICTPR)**Arm A:** MSCs\
**Arm B:** standard treatment60UnspecifiedUnspecifiedNot recruitingChina (Hunan yuanpin Cell Biotech)ChiCTR2000030020 (ICTPR)**Arm A:** MSCs20NoNoRecruitingChinaChiCTR2000029990 (ICTPR) \[[@bb0110]\]**Arm A:** MSCs\
**Arm B:** saline120YesUnspecifiedRecruitingChinaChiCTR2000030261 (ICTPR)**Arm A:** MSC-derived exosomes\
**Arm B:** standard treatment26UnspecifiedUnspecifiedNot recruitingChinaNCT04280224 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0230})**Arm A:** NK cells\
**Arm B:** standard treatment30YesNoRecruitingChinaChiCTR2000030509 (ICTPR)**Arm A:** NK cells\
**Arm B:** electrolyte injection40UnspecifiedUnspecifiedNot recruitingChinaChiCTR2000030944 (ICTPR)**Arm A:** NK cells and MSC\
**Arm B:** standard treatment20YesNoNot recruitingChinaNCT04302519 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0235})**Arm A:** pulp MSCs24NoNoNot recruitingChina (CAR-T Biotechnology Co, Ltd)ChiCTR2000029580 (ICTPR)**Arm A: ruxolitinib** and MSCs\
**Arm B:** standard treatment70YesSingleRecruitingChinaNCT04299152 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0240})**Arm A: stem cell educator therapy**\
**Arm B:** standard treatment20YesSingleNot recruitingUSA (Tianhe Stem Cell Biotechnologies Inc)ChiCTR2000030329 (ICTPR)**Arm A:** umbilical cord blood **CIK** cells\
**Arm B** umbilical cord NK cells\
**Arm C:** standard treatment90UnspecifiedUnspecifiedNot recruitingChinaChiCTR2000029812 (ICTPR)**Arm A:** umbilical cord blood mononuclear cell preparations\
**Arm B:** standard treatment60UnspecifiedUnspecifiedNot recruitingChina (Guangzhou Reborn Health Management Consultation Co)ChiCTR2000029572 (ICTPR)**Arm A:** umbilical cord blood mononuclear cells\
**Arm B:** standard treatment30YesUnspecifiedRecruitingChinaChiCTR2000029818 (ICTPR)**Arm A:** umbilical cord blood plasma preparations\
**Arm B:** standard treatment60UnspecifiedUnspecifiedNot recruitingChina (Guangzhou Reborn Health Management Consultation Co)NCT04293692 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0245})**Arm A:** umbilical cord MSCs\
**Arm B:** placebo48YesTripleWithdrawnChina (Wuhan Hamilton Biotechnology)NCT04273646 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0250})**Arm A:** umbilical cord MSCs\
**Arm B:** placebo48YesNoNot recruitingChina (Wuhan Biotechnology)NCT04269525 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0255})**Arm A:** umbilical cord MSCs10NoNoRecruitingChina (Tuohua Biological Technology Co)ChiCTR2000030138 (ICTPR)**Arm A:** umbilical cord MSCs\
**Arm B:** placebo60YesDoubleNot recruitingChinaChiCTR2000030484 (ICTPR)**Arm A:** umbilical cord MSCs\
**Arm B:** umbilical cord MSCs and derived exosomes\
**Arm C:** placebo120UnspecifiedUnspecifiedNot recruitingChinaChiCTR2000030116 (ICTPR)**Arm A:** umbilical cord MSCs dose A\
**Arm B** umbilical cord MSCs dose B16YesUnspecifiedRecruitingChinaChiCTR2000029816 (ICTPR)**Arm A:** umbilical cord MSCs\
**Arm B:** standard treatment60YesNoNot recruitingChina (Guangzhou Reborn Health Management)NCT04313322 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0260})**Arm A:** Wharton jelly MSCs5NoNoRecruitingJordan (Stem Cells Arabia)ChiCTR2000030088 (ICTPR)**Arm A:** Wharton jelly MSCs\
**Arm B:** saline20YesUnspecifiedNot recruitingChina**Plasma-based therapy**ChiCTR2000030702 (ICTPR)**Arm A:** convalescent plasma therapy\
**Arm B:** standard treatment50YesNoRecruitingChinaChiCTR2000030046 (ICTPR)**Arm A:** anti-2019-nCoV virus inactivated plasma10NoNoRecruitingChinaChiCTR2000030381 (ICTPR)**Arm A:** anti-SARS-CoV-2 inactivated convalescent plasma\
**Arm B:** ordinary plasma40YesNoNot recruitingChinaChiCTR2000030010 (ICTPR)**Arm A:** anti-SARS-CoV-2 virus inactivated plasma\
**Arm B:** ordinary plasma100YesDoubleNot recruitingChinaChiCTR2000030841 (ICTPR)**Arm A:** convalescent immunoglobulin\
**Arm B:** gamma-globulin10NoNoRecruitingChinaNCT04264858 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0265})**Arm A:** convalescent immunoglobulin\
**Arm B:** gamma globulin10NoNoNot recruitingChinaChiCTR2000030039 (ICTPR)**Arm A:** convalescent plasma\
**Arm B:** standard treatment90NoNoRecruitingChinaChiCTR2000029850 (ICTPR)**Arm A:** convalescent plasma\
**Arm B:** standard treatment20NoUnspecifiedRecruitingChinaChiCTR2000030627 (ICTPR)**Arm A:** convalescent plasma therapy\
**Arm B:** standard treatment30YesUnspecifiedRecruitingChinaChiCTR2000029757 (ICTPR)**Arm A:** convalescent plasma therapy\
**Arm B:** standard treatment200YesNoRecruitingChinaChiCTR2000030929 (ICTPR)**Arm A:** convalescent plasma therapy\
**Arm B:** control plasma60YesDoubleNot recruitingChinaChiCTR2000030179 (ICTPR)**Arm A:** plasma treatment\
**Arm B:** standard treatment100YesUnspecifiedRecruitingChina**Inhaled gas**ChiCTR2000030258 (ICTPR)**Arm A:** hydrogen inhalation[e](#tf0025){ref-type="table-fn"}\
**Arm B:** standard treatment60YesNoNot recruitingChinaChiCTR2000029739 (ICTPR)**Arm A:** hydrogen--oxygen nebuliser\
**Arm B:** oxygen440YesUnspecifiedRecruitingChinaNCT04290871 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0270})**Arm A:** inhaled nitric oxide\
**Arm B:** no intervention104YesYesNot yet recruitingChinaNCT04306393 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0275})**Arm A:** inhaled nitric oxide\
**Arm B:** no intervention200YesYesNot yet recruitingUSANCT04305457 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0280})**Arm A:** inhaled nitric oxide\
**Arm B:** no intervention240YesNoNot yet recruitingUSANCT04290858 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0285})**Arm A:** inhaled nitric oxide\
**Arm B:** no intervention240YesNoNot yet recruitingChina**Antifibrotic**NCT04282902 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0290})**Arm A:** pirfenidone\
**Arm B:** standard treatment294YesNoRecruitingChinaChiCTR2000030892 (ICTPR)**Arm A:** pirfenidone\
**Arm B:** standard treatment20YesNoRecruitingChinaChiCTR2000030333 (ICTPR)**Arm A:** pirfenidone\
**Arm B:** standard treatment292YesNoRecruitingChina**Antiangiogenic**NCT04275414 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0295})**Arm A:** bevacizumab20NoNoRecruitingChinaNCT04305106 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0300})**Arm A:** bevacizumab\
**Arm B:** standard treatment118YesTripleRecruitingChinaNCT04273581 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0305})**Arm A:** thalidomide\
**Arm B:** placebo40YesQuadrupleNot recruitingChinaNCT04273529 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0310})**Arm A:** thalidomide\
**Arm B:** placebo100YesQuadrupleNot recruitingChina**Antimicrobial**ChiCTR2000030539 (ICTPR)**Arm A:** 3% hydrogen peroxide gargle\
**Arm B:** standard treatment40UnspecifiedUnspecifiedNot recruitingChinaChiCTR2000029867 (ICTPR)**Arm A: carrimycin**\
**Arm B:** lopinavir/ritonavir520YesNoRecruitingChinaNCT04286503 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0315})**Arm A:** carrimycin + basic treatment (unspecified)\
**Arm B:** lopinavir/ritonavir or umifenovir or chloroquine phosphate + basic treatment (unspecified)520YesNoRecruitingChina (Shenyang Tonglian Group)ChiCTR2000030029 (ICTPR)**Arm A: suramin**20NoNoNot yet recruitingChina**Antioxidants**ChiCTR2000029851 (ICTPR)**Arm A:** alpha **lipoic acid**\
**Arm B:** placebo68YesUnspecifiedRecruitingChinaChiCTR2000030471 (ICTPR)**Arm A:** lipoic acid injection\
**Arm B:** standard treatment384YesSingleRecruitingChina**Microbiome**ChiCTR2000030897 (ICTPR)**Arm A:** Newgen beta-gluten probiotic\
**Arm B:** standard treatment20YesUnspecifiedRecruitingChinaChiCTR2000029999 (ICTPR)**Arm A:** probiotics\
**Arm B:** probiotics60NoNoNot recruitingChinaChiCTR2000029974 (ICTPR)**Arm A:** probiotics\
**Arm B:** standard treatment300YesNoRecruitingChina (Qingdao East Sea Pham.)ChiCTR2000029849 (ICTPR)**Arm A:** Unspecified intestinal flora intervention\
**Arm B:** standard treatment60YesUnspecifiedRecruitingChinaNCT04251767 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0320})**Arm A:** washed microbiota transplant\
**Arm B:** placebo40YesQuadrupleEnrolling by invitationChina**Organ support**ChiCTR2000030503 (ICTPR)**Arm A:** artificial liver system\
**Arm B:** standard treatment60NoNoRecruitingChinaChiCTR2000030540 (ICTPR)**Arm A:** CRRT\
**Arm B:** CRRT only for emergency indication152UnspecifiedUnspecifiedNot recruitingChinaChiCTR2000030761 (ICTPR)**Arm A:** CRRT20NoNoNot recruitingChinaChiCTR2000030744 (ICTPR)**Arm A:** ECMO\
**Arm B:** standard treatment30NoNoRecruitingChinaChiCTR2000030855 (ICTPR)**Arm A:** external diaphragmatic pacing200NoNoNot recruitingChinaChiCTR2000030773 (ICTPR)**Arm A:** Unspecified blood purification20NoNoRecruitingChina**Therapy interventions**ChiCTR2000030260 (ICTPR)**Arm A:** enteral nutrition emulsion\
**Arm B:** standard treatment20YesNoNot recruitingChinaChiCTR2000030198 (ICTPR)**Arm A:** health education and pulmonary rehabilitation\
**Arm B:** health education60UnspecifiedUnspecifiedNot recruitingChinaChiCTR2000030418 (ICTPR)**Arm A:** lung rehabilitation\
**Arm B:** usual activity80UnspecifiedUnspecifiedRecruitingChinaChiCTR2000030578 (ICTPR)**Arm A:** lung rehabilitation training\
**Arm B:** standard treatment40UnspecifiedUnspecifiedNot recruitingChinaNCT04283825 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0325})**Arm A:** psychological and physical rehabilitation\
**Arm B:** standard treatment100NoNoNot recruitingChinaChiCTR2000030084 (ICTPR)**Arm A:** psychological intervention\
**Arm B:** standard treatment180UnspecifiedUnspecifiedRecruitingChinaChiCTR2000030467 (ICTPR)**Arm A:** psychological intervention and traditional Chinese medicine\
**Arm B:** psychological intervention, traditional Chinese medicine, and traditional Chinese medicine psychological intervention60UnspecifiedUnspecifiedNot recruitingChinaChiCTR2000029459 (ICTPR)**Arm A:** pulmonary rehabilitation\
**Arm B:** standard treatment50UnspecifiedUnspecifiedNot recruitingChinaChiCTR2000030433 (ICTPR)**Arm A:** rehabilitation and lung eight-segment exercise[f](#tf0030){ref-type="table-fn"}80NoNoNot recruitingChinaChiCTR2000029460 (ICTPR)**Arm A:** shadowboxing rehabilitation\
**Arm B:** standard treatment100YesNoNot recruitingChina**Ozonated autohemotherapy**ChiCTR2000030165 (ICTPR)**Arm A:** conventional treatment\
**Arm B** (mild): conventional treatment + ozonated autohemotherapy\
**Arm C** (severe): conventional treatment + ozonated autohemotherapy60NoNoRecruitingChinaChiCTR2000030102 (ICTPR)**Arm A:** conventional treatment\
**Arm B:** conventional treatment + ozone therapy\
**Arm C** (severe): conventional treatment + ozone therapy\
**Arm D** (severe): conventional treatment\
**Arm E** (critical): conventional treatment + ozone therapy\
**Arm F** (critical): conventional treatment180YesNoRecruitingChinaChiCTR2000030006 (ICTPR)**Arm A:** ozonated autohemotherapy\
**Arm B:** standard medical treatment60YesNoRecruitingChina**Other**ChiCTR2000029742 (ICTPR)**Arm A:** (general): normal treatment\
**Arm B** (general): normal treatment + **sodium aescinate**\
**Arm C** (severe): normal treatment + hormonotherapy (presumed glucocorticoids)\
**Arm D** (severe): lopinavir/ritonavir\
**Arm E** (severe)**:** normal treatment + sodium aescinate90YesNoRecruitingChinaChiCTR2000030328 (ICTPR)**Arm A:** acetylcysteine inhalation (mucolytic effect) via tracheal tube\
**Arm B:** saline inhalation via tracheal tube60YesUnspecifiedNot recruitingChinaChiCTR2000030398 (ICTPR)**Arm A: bismuth**\
**Arm B:** placebo340YesDoubleNot recruitingChinaChiCTR2000030055 (ICTPR)**Arm A:** conventional treatment\
**Arm B:** conventional treatment + **dipyridamole**460YesNoRecruitingChinaChiCTR2000030853 (ICTPR)**Arm A: dexmedetomidine**200NoNoNot recruitingChinaChiCTR2000030700 (ICTPR)**Arm A: enoxaparin** sodium\
**Arm B:** standard treatment60YesNoNot recruitingChinaChiCTR2000030135 (ICTPR)**Arm A:** high-dose vitamin C\
**Arm B:** standard treatment39YesUnspecifiedNot recruitingChinaNCT04311697 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0330})**Arm A:** intravenous **aviptadil** followed by nebulised in 48 h if required\
**Arm B:** aviptadil nebuliser followed by intravenous in 48 h if required20YesSingleNot recruitingUSA and Israel (NeuroRx)ChiCTR2000030170 (ICTPR)**Arm A:** jakotinib[g](#tf0035){ref-type="table-fn"}8UnspecifiedUnspecifiedRecruitingChinaNCT04312009 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0335})**Arm A: losartan**\
**Arm B:** placebo200YesQuadrupleNot recruitingUSANCT04311177 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0340})**Arm A:** losartan\
**Arm B:** placebo478YesQuadrupleNot recruitingUSAChiCTR2000030946 (ICTPR)**Arm A:** low-molecular-weight heparin\
**Arm B:** mechanical prevention120YesUnspecifiedRecruitingChinaNCT04304313 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0345})**Arm A: sildenafil**10NoNoRecruitingChinaNCT04308317 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0350})**Arm A: tetrandrine**\
**Arm B:** standard treatment60YesNoEnrolling by invitationChinaNCT04264533 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0355})**Arm A:** vitamin C\
**Arm B:** sterile water for injection140YesTripleRecruitingChina**(B) Ongoing clinical trials for prevention of COVID-19Vaccine**NCT04299724 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0360})**Arm A:** Covid-19/aAPC vaccine100NoNoRecruitingChinaNCT04313127 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0365})**Arm A:** low-dose Ad5-nCoV\
**Arm B:** middle-dose Ad5-nCoV\
**Arm C:** high-dose Ad5-nCoV108NoNoNot recruitingChina (CanSino Biologics)NCT04283461 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0370})**Arm A:** mRNA-1273 (25 μg)\
**Arm B:** mRNA-1273 (100 μg)\
**Arm C:** mRNA-1273 (250 μg)45NoNoRecruitingUSA (ModernaTX)**Antiviral**NCT04304053 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0375})**Arm A:** darunavir/cobicistat\
**Arm B:** isolation3040YesNoRecruitingSpainChiCTR2000030013 (ICTPR)**Arm A:** interferon a1b\
**Arm B:** no intervention450UnspecifiedUnspecifiedNot recruitingChinaChiCTR2000029592 (ICTPR)**Arm A:** umifenovir\
**Arm B:** without umifenovir1000UnspecifiedNoNot recruitingChina**Antimalarial**NCT04303507 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0380})**Arm A:** chloroquine\
**Arm B:** placebo10000YesDoubleNot recruitingUKNCT04308668 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0385})**Arm A:** hydroxychloroquine\
**Arm B:** placebo1500YesQuadrupleRecruitingUSAChiCTR2000029803 (ICTPR)**Arm A:** hydroxychloroquine (low dose)\
**Arm B:** hydroxychloroquine -- high dose\
**Arm C:** umifenovir -- low dose\
**Arm D:** umifenovir -- high dose320YesNoNot recruitingChina**Personal protective equipment**ChiCTR2000030317 (ICTPR)**Arm A:** gastroscope mask\
**Arm B:** without mask300YesNoNot recruitingChinaNCT04296643 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0390})**Arm A:** medical masks\
**Arm B:** N95 respirators676YesSingleNot recruitingUSA**Other**NCT04312243 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0395})**Arm A:** nitric oxide\
**Arm B:** no treatment460NoNoNot recruitingUSANCT04313023 ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0400})**Arm A:** PUL-042\
**Arm B:** normal saline200YesQuadrupleNot yet recruitingUSA (Pulmotect)ChiCTR2000030432 (ICTPR)**Arm A:** rehabilitation and lung eight-segment exercises\
**Arm B:** normal activity80YesNoNot recruitingChina[^2][^3][^4][^5][^6][^7][^8]

Treatment Strategies {#s0015}
====================

Antiviral Treatments {#s0020}
--------------------

As briefly mentioned earlier, many studies have focused on repurposing established antiviral therapies, especially those that showed prior efficacy against SARS-CoV and MERS-CoV. The combination of lopinavir/ritonavir is the most common exploratory antiviral, appearing in 34 investigational studies ([Table 1](#t0005){ref-type="table"}A: Antivirals). Both drugs function as protease inhibitors and are used extensively in the management of HIV-1 \[[@bb0045]\]. However, lopinavir has insufficient oral bioavailability for significant therapeutic activity, due to rapid catabolism by the cytochrome P450 enzyme system (specifically 3A4 isoenzyme) \[[@bb0045]\]. Thus, ritonavir is given concomitantly to inhibit this, significantly boosting the half-life of lopinavir. Lopinavir/ritonavir was investigated for efficacy against SARS-CoV in 2004 and found to be effective compared with a historical control \[[@bb0050]\]. However, efficacy was not seen in a **randomised open-label study** (see [Glossary](#gs0005){ref-type="list"}) (lopinavir/ritonavir versus standard care) in 199 patients with COVID-19 (Clinical Trial Number: ChiCTR2000029308, recruitment target stated as 160 participants in the registry; [Table 1](#t0005){ref-type="table"}). No significant benefit was seen in either overall mortality or reduction in viral load \[[@bb0055]\]. The authors highlighted several limitations, including a lack of treatment **blinding**, with study participants and investigators being aware of treatment assignments, thus reducing study objectivity. While there are multiple other ongoing studies exploring lopinavir/ritonavir in COVID-19, none utilises a **double-blind** methodology to address this limitation.

Remdesivir is a novel nucleotide analogue antiviral, initially developed for the management of the Ebola and Marburg viruses \[[@bb0060],[@bb0065]\]. However, it has efficacy against a range of pathogenic viruses, including both SARS-CoV and MERS-CoV in *in vitro* and *in vivo* models \[[@bb0060],[@bb0070]\]. There has been much interest in this molecule, following treatment of the first COVID-19 case, and subsequent recovery, in the USA \[[@bb0075]\]. There are currently ten registered trials taking place globally to investigate efficacy for COVID-19 ([Table 1](#t0005){ref-type="table"}A: Antivirals).

Several other antiviral drugs are being investigated, predominately those with activity against various influenza subtypes and other RNA viruses. These include **favipiravir** (T-705, Avigan), **umifenovir** (Arbidol), **triazavirin** (TZV), and **baloxavir marboxil** (Xofluza). Many trials are focusing on drugs typically used in the management of RNA viruses, such as HCV and HIV. These include **danoprevir**/ritonavir, **azvudine**, **sofosbuvir/ledipasvir**, **sofosbuvir/daclatasvir**, **darunavir**/**cobicistat,** and **emtricitabine/** **tenofovir** ([Table 1](#t0005){ref-type="table"}A: Antivirals). Additionally, there are 26 studies investigating the utility of antiviral interferon-based treatments, interestingly also looking at various different routes of administration (e.g., nasal).

Antimalarial Treatments {#s0025}
-----------------------

Thirty-five trials are now investigating the use of the antimalarial drugs chloroquine and hydroxychloroquine against COVID-19 ([Table 1](#t0005){ref-type="table"}A: Antimalarials). Chloroquine was found to have significant inhibitory effects on viral cell entry and replication *in vitro* \[[@bb0060]\]. An early report of clinical experience in 100 patients with COVID-19 reported both beneficial clinical and virological outcomes with chloroquine treatment \[[@bb0080]\]. More recently, a nonrandomised open-label study examining the effect of hydroxychloroquine (EU Clinical Trial Number[vii](#p0155){ref-type="p"}: 2020-000890-25; recruitment target stated as 25 participants in the registry) reported on a cohort of 36 patients \[[@bb0085]\]. It reported a significant reduction in nasopharyngeal swab viral positivity 6 days after inclusion in the hydroxychloroquine group compared with control. However, in a deviation from their registry-described protocol, 16 patients were designated as controls and six patients received concurrent treatment with azithromycin to prevent bacterial superinfection. Selection of patients receiving azithromycin was based on clinical judgement. The subgroup receiving azithromycin all had negative viral swabs after 6 days compared with 57% (8/14) of hydroxychloroquine alone and 12.5% (2/16) of control \[[@bb0085]\]. This study is limited by its lack of randomisation and blinding, and small sample size. There is much interest in chloroquine or hydroxychloroquine for the treatment of COVID-19, with a further 34 studies registered ([Table 1](#t0005){ref-type="table"}A: Antimalarials); however, only four report using a robust double-blind randomised controlled protocol to investigate efficacy.

Immunosuppressants/Immunomodulators {#s0030}
-----------------------------------

There is evidence that a hyperinflammatory response significantly contributes to mortality in COVID-19 infections \[[@bb0090]\]. Corticosteroids were previously trialled in SARS-CoV; however, the results were inconclusive and adverse effects were associated \[[@bb0095]\]. Seven registered studies are evaluating the effect of corticosteroids in COVID-19 ([Table 1](#t0005){ref-type="table"}A: Immunosuppressants). There is also interest in the anti-IL-6 drug, tocilizumab (used in the treatment of rheumatoid arthritis), with seven registered trials. Other immunosuppressants being investigated include **adalimumab** (anti-TNF), **eculizumab** (anti-C5), sarilumab (anti-IL-6), ixekizumab (anti-17A), and fingolimod (sphingosine-1-phosphate receptor modulator, used against multiple sclerosis). Meplazumab (anti-CD147) inhibits not only T cell chemotaxis, but also virus cell entry \[[@bb0100]\]. A preprint of a study of 17 patients compared with 11 controls (NCT04275245, original recruitment target 20) reported improved clinical and virological outcomes \[[@bb0100]\].

Conversely, several studies are investigating immune stimulation. These include the **anti-PD-1** antibody camrelizumab, **recombinant IL-2**, CSA0001 (LL-37 antiviral peptide with immunomodulatory functions), CD24FC \[fusion protein that prevents Toll-like receptor (TLR) activation and activates immunosuppressive Siglec signalling\] and recombinant human granulocyte colony-stimulating factor (rhG-CSF) ([Table 1](#t0005){ref-type="table"}A: Immune Modulators). Three studies (NCT04299724, NCT04276896, and ChiCTR2000030750) examine the efficacy of experimental vaccines in infected patients. Three further studies are investigating nonpharmaceutical interventions to modulate the immune system using cytokine filtration devices, such as oXiris and CytoSorb, to reduce circulating cytokines and inflammatory mediators ([Table 1](#t0005){ref-type="table"}A: Cytokine Removal).

Cell and Plasma-Based Therapy {#s0035}
-----------------------------

Twenty-four registered studies plan to investigate the role of mesenchymal stem cells (MSCs) ([Table 1](#t0005){ref-type="table"}A: Cell-Based Therapies). MSCs have immunomodulatory and tissue repair effects through the secretion of cytokines and growth factors. They have previously been examined in a Phase I trial in Adult Respiratory Distress Syndrome (ARDS) \[[@bb0105]\]. Given that most of the deaths in COVID-19 are from respiratory failure, MSCs are postulated to have a beneficial effect. So far, one study of MSCs (ChiCTR2000029990, recruitment target stated as 120 participants in the registry) has reported results in seven patients with COVID-19, showing improvement in both clinical and inflammatory outcome compared with three control patients treated with saline \[[@bb0110]\]. This study plans to recruit 120 participants with 60 patients in each of the treatment (MSC) and control (saline) arms.

Use of plasma from patients who have recovered from COVID-19 has the potential benefit of providing disease-specific neutralising antibodies, before targeted therapies can be developed. During the Ebola outbreak in 2014, the WHO advised the use of convalescent plasma or whole-blood therapies. However, a nonrandomised comparative study in 84 patients with Ebola found no associated improvement in survival \[[@bb0115]\]. There are currently 12 registered trials to investigate convalescent plasma or immunoglobulins in COVID-19 ([Table 1](#t0005){ref-type="table"}A: Plasma-Based Therapies).

Alternative Treatment Strategies {#s0040}
--------------------------------

Various other treatment strategies are currently under investigation, including the antifibrotic/inflammatory agent pirfenidone (used in treatment of idiopathic pulmonary fibrosis), and the antiangiogenic agents: **bevacizumab** (anti-VEGF) and **thalidomide** ([Table 1](#t0005){ref-type="table"}A: Antifibrotics and Antiangiogenics). A further five studies aim to assess the therapeutic utility of modifying the gut microbiome ([Table 1](#t0005){ref-type="table"}A: Microbiome), although the mechanisms by which this is performed are not explicit in the trial registers. Ten other studies are investigating holistic approaches, including physiotherapy, psychology, and nutritional intervention, on disease outcome ([Table 1](#t0005){ref-type="table"}A: Therapy Interventions).

Preventative Strategies {#s0045}
=======================

No effective vaccine or antiviral therapeutic agent for postexposure prophylaxis has been approved for preventing COVID-19 infection or any other human coronavirus. The development of vaccines is a complex, time-consuming process with a high attrition rate. Success in generating a vaccine in the recent 2009 flu pandemic (H1N1/09) has fuelled optimism towards one for COVID-19 \[[@bb0120]\]. Furthermore, both the rapid genomic sequencing of COVID-19 and insights gleaned during vaccine exploration for both MERS-CoV and SARS-CoV (both terminated due to successful disease containment) has allowed preclinical and animal work to advance rapidly \[[@bb0035]\].

Over 50 novel vaccines are estimated to be in development; however, only three vaccine studies are registered for Phase I evaluation ([Table 1](#t0005){ref-type="table"}B: Vaccines). Two studies are actively recruiting in the USA and China, and a further study is newly registered (initial set-up). A modified mRNA vaccine (mRNA-1273) that encodes the COVID-19 viral spike protein has progressed rapidly through preclinical development to human testing (42 days from sequence identification), developed by Moderna, Inc and the National Institute of Allergy and Infectious Diseases (NIAID). However, such rapid development has prompted safety concerns from some experienced virologists \[[@bb0125]\]. Other current investigational vaccines being tested in humans include a replicative-defective adenovirus type 5 (Ad5)-nCoV that expresses COVID-19 viral proteins and a lentiviral vector system to express viral proteins and immunomodulatory genes to modify antigen-presenting cells (aAPC) ([Table 1](#t0005){ref-type="table"}B: Vaccines).

Furthermore, postexposure prophylaxis is an attractive strategy for both healthcare workers and household contacts exposed to COVID-19. Currently, six studies are looking at the use of antivirals, such as umifenovir, antimalarials, such as hydroxychloroquine and chloroquine, and the use of recombinant human **interferon** **alpha** (a)1b spray for the prevention of infection ([Table 1](#t0005){ref-type="table"}B: Antiviral and Antimalarial).

Global Response {#s0050}
===============

Over 85% of the clinical trials (excluding TCM) for either the prevention and/or treatment of COVID-19 have been registered in China, which is not surprising given that the country saw the outbreak of the disease first. The first clinical trials were registered within 1 month of COVID-19 identification and rapidly expanded after that ([Figure 2](#f0010){ref-type="fig"} ). Public health initiatives have thus far successfully curtailed the previously exponential growth of COVID-19 cases in China. This has reduced the number of potential participants for clinical trials in China and the registration of new clinical trials has since declined. Furthermore, several studies have also been withdrawn or suspended (e.g., NCT04293692 and ChiCTR2000030082).Figure 2First Recording (Week Commencing) of Clinical Trials for COVID-19 in Registry by Country (Primary Sponsor/Principal Investigator Origin).Data are from registries in Australia, New Zealand, China, The Netherlands, Brazil, India, Cuba, Republic of Korea, Germany, Iran, Japan, Sri Lanka, Thailand, and Peru, and also [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0010}, EU Clinical Trials registry, International Standard Randomised Controlled Trial Number (ISRCTN), and the Pan-Africa registries.Figure 2

The wider global community has been slower to react. The first case of COVID-19 outside of Asia was reported in late January 2020[iii](#p0135){ref-type="p"}. Subsequently, the incidence of COVID-19 has increased dramatically. The WHO has now declared that Europe has become the new disease epicentre, with 40% and rising of the total number of cases[ix](#p0165){ref-type="p"}. However, until recently, \<5% of clinical trials for COVID-19 were registered in Europe ([Figure 2](#f0010){ref-type="fig"}). The rapid escalation of trial registrations in response to increasing disease incidence seen in China has unfortunately not occurred in Europe. Despite this, there are now encouraging signs. Initiatives focused on pan-European collaboration are being championed by the European Union with a priority on larger patient studies compared with the smaller studies registered in China[x](#p0170){ref-type="p"}. Consequently, the median number of participants in European registered studies is 1200 participants, compared with 60 and 394 in China and USA, respectively. An example is NCT04303507 (chloroquine postexposure prophylaxis), which plans to recruit 10 000 participants ([Table 1](#t0005){ref-type="table"}B). However, this may in part reflect a higher proportion of preventative studies currently being carried out that include large numbers of participants. Hopefully, larger studies will provide higher quality evidence, although may take longer to generate results in the context of this escalating public health crisis.

With an increasing number of COVID-19 cases reported in North America, there has also been an increase in clinical trial registrations in the USA. The NIAID registered the first USA-led global trial in mid-February 2020, utilising 50 sites across Asia and USA ([Figure 2](#f0010){ref-type="fig"}). Studies registered in the USA have generally placed an emphasis on larger participant numbers than China ([Table 1](#t0005){ref-type="table"}) and on an adaptive trial design for both the treatment and prevention of COVID-19.

Concluding Remarks {#s0055}
==================

The COVID-19 pandemic represents the gravest global public health threat seen since the 1918 influenza outbreak and has rapidly become a global healthcare emergency. Clinical trials need to produce high-quality data that can be used to objectively assess potentials therapies for both the treatment and prevention of this global emergency. It is imperative to plough international resources into high-quality design clinical trials with robust scientific rationale and vigorous statistical rigor. Increasing international collaboration and the globalisation of clinical trials with large patient numbers should be the way forward to provide significant and definitive results.
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**Adalimumab**

:   mAb targeted against TNF-α; an immunosuppressant commonly used in inflammatory conditions.

**Anti-PD-1 antibody**

:   antibody against Programmed Cell Death Protein 1 (PD-1); inhibition of PD-1 can reverse immune exhaustion; used in oncology treatment (e.g., melanoma).

**ASC09**

:   HIV protease inhibitor; under development by Ascletis Pharmaceuticals.

**Aviptadil**

:   a vasodilator and short-acting alpha-adrenoreceptor antagonist.

**Azvudine**

:   nucleoside reverse transcriptase inhibitor with efficacy against HCV and HIV.

**Baloxavir marboxil**

:   polymerase acidic endonuclease inhibitor approved for influenza.

**Bevacizumab**

:   mAb targeting vascular endothelial growth factor (VEGF).

**Bismuth**

:   oral medication used in treatment of *Helicobacter pylori*; some evidence of inhibition of SARS coronavirus helicase ATPase.

**Blinding**

:   experimental procedure in which the participant, investigator, care provider, or outcome assessor in a clinical trial are unaware of which treatment arm the participant is receiving. Studies can be described as the number of roles that are blinded (i.e., single, double or quadruple-blinded study). Blinding reduces the risk of bias in the outcome of a trial.

**Carrimycin**

:   macrolide antibiotic.

**Cytokine-induced killer cells (CIK cell)**

:   CD8^+^ T cells expanded from *ex vivo* stimulation of lymphocytes; used in experimental immunotherapy.

**Cobicistat**

:   CYP3A inhibitor licensed for use in HIV; potentiates action of other antiviral medication.

**Danoprevir**

:   NS3/4A protease inhibitor used in treatment of HCV.

**Darunavir**

:   HIV protease inhibitor.

**Dexmedetomidine**

:   sedative α2-adrenergic receptor agonist.

**Dihydroartemisinin/piperaquine**

:   combination antimalarial medication.

**Dipyridamole**

:   antiplatelet medication that is a phosphodiesterase inhibitor; exerts antiviral effects via inhibition of nucleoside uptake.

**Double-blind**

:   where two groups within a study, typically the participant and the outcome assessor, are blinded to the treatment received by the participant.

**Ebastine**

:   H~1~ receptor antagonist.

**Eculizumab**

:   mAb that inhibits activation of complement protein C5; used in thrombotic microangiopathy.

**Emtricitabine/tenofovir**

:   combination nucleoside reverse transcriptase inhibitor used in the treatment of HIV-1.

**Enoxaparin**

:   low-molecular-weight heparin, an anticoagulant.

**Favipiravir**

:   RNA-dependent RNA polymerase inhibitor, investigated against RNA viruses, such as Influenza, Ebola and Marburg viruses.

**GD31**

:   described within the trial report as novel nucleoside analogue.

**Interferon alpha**

:   cytokine used in the treatment of chronic viral infections, such as HBV and HCV.

**Interferon beta 1b**

:   cytokine used in the treatment of multiple sclerosis.

**Leflunomide**

:   immunosuppressive used in the treatment of rheumatoid arthritis.

**Lipoic acid**

:   antioxidant.

**Losartan**

:   angiotensin-II receptor antagonist.

**Novaferon**

:   recombinant interferon-like protein; *in vitro* and *in vivo* model evidence of more potent activity compared with interferon.

**Open-label**

:   a study in which the treatment received by the participant is known to both the participant and investigators.

**Oseltamivir**

:   neuraminidase inhibitor; licenced for influenza A and B treatment.

**Pegasys**

:   pegylated interferon alpha 2a.

**Polyinosinic-polycytidylic acid**

:   immunostimulant; TLR3 agonist.

**PUL-042**

:   immunostimulant; TLR2/6/9 agonist.

**Randomised study**

:   a trial in which the treatment or intervention is randomly allocated to a participant. Randomisation reduces the risk of bias in a trial outcome.

**Recombinant IL-2**

:   cytokine used in cancer immunotherapy treatment (e.g., melanoma).

**Ribavirin**

:   guanosine analogue; antiviral agent used against a range of morbific viral infections (e.g., HCV, human respiratory syncytial virus, and Lassa virus).

**Ruxolitinib**

:   selective inhibitor of Janus Kinase type 1 and 2; used within haematology against polycythaemia vera and myelofibrosis.

**Sildenafil**

:   phosphodiesterase type 5 inhibitor; vasodilator used commonly for erectile dysfunction and pulmonary arterial hypertension.

**Sodium aescinate**

:   saponin extract of *Aesculus hippocastanum* seeds; investigated for use in lung injury.

**Sofosbuvir/daclatasvir**

:   combination mediation used in treatment of HCV. Sofosbuvir is a nucleotide prodrug and acts as an inhibitor of HCV NS5B RNA-dependant RNA polymerase. Daclatasvir is an HCV NS5A inhibitor.

**Sofosbuvir/ledipasvir**

:   combination mediation used in treatment of HCV; Ledipasvir is an inhibitor of HCV NS5A protein.

**Stem cell educator therapy**

:   circulation of patient blood through a cell separator followed by brief co-culture of immune cells with cord-blood stem cells and return of the educated immune cells to the patient's circulation.

**Suramin**

:   antitrypanosomal drug used in treatment of African trypanosomiasis.

**Tetrandrine**

:   bisbenzylisoquinoline alkaloid; a calcium channel blocker with anti-inflammatory and immunosuppressant properties.

**Thalidomide**

:   antiangiogenic and immunomodulator used against a range of haematological malignancies, including multiple myeloma. Teratogenic antiemetic causing range of birth defects, such as phocomelia.

**Thymosin**

:   thymus hormones that stimulate development of T cells.

**Tranilast**

:   antiallergic analogue of a tryptophan metabolite; NLRP3 inflammasome inhibitor.

**Triazavirin**

:   guanine nucleotide analogue with broad-spectrum antiviral effects.

**Umifenovir (Arbidol)**

:   non-nucleoside antiviral membrane fusion inhibitor; licensed in Russia for the treatment of influenza.

Resources {#s0065}
=========

^i^ [www.who.int/csr/sars/country/table2004_04_21/en/](http://www.who.int/csr/sars/country/table2004_04_21/en/){#ir0405}

^ii^ [www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19](http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19){#ir0410}

^iii^ [www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports](http://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports){#ir0415}

^iv^ <https://unctad.org/en/pages/newsdetails.aspx?OriginalVersionID=2300>

^v^ <https://clinicaltrials.gov>

^vi^ [www.who.int/ictrp/en/](http://www.who.int/ictrp/en/){#ir0430}

^vii^ [www.clinicaltrialsregister.eu/](http://www.clinicaltrialsregister.eu/){#ir0435}

^viii^ [www.cochranelibrary.com/central/about-central](http://www.cochranelibrary.com/central/about-central){#ir0440}

^ix^ [www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/global-solidarity-across-countries-and-continents-needed-to-fight-covid-19](http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/global-solidarity-across-countries-and-continents-needed-to-fight-covid-19){#ir0445}

^x^ [www.bioworld.com/articles/433824-eu-boosts-funding-for-covid-19-epidemic-encourages-clinical-trial-cooperation](http://www.bioworld.com/articles/433824-eu-boosts-funding-for-covid-19-epidemic-encourages-clinical-trial-cooperation){#ir0450}

^xi^ [www.isrctn.com/?gclid=Cj0KCQjwjoH0BRD6ARIsAEWO9Dt7ppI5xmcUMgabefiiRnPVSbsoH3CtwieB5maS2z4gzAyZ1nNjd8MaAjEREALw_wcB](http://www.isrctn.com/%3fgclid=Cj0KCQjwjoH0BRD6ARIsAEWO9Dt7ppI5xmcUMgabefiiRnPVSbsoH3CtwieB5maS2z4gzAyZ1nNjd8MaAjEREALw_wcB){#ir0455}

[^1]: These authors contributed equally

[^2]: Abbreviations: Ad5, adenovirus type 5; APC, antigen-presenting cells; CIK cells, **cytokine-induced killer cells**; CRRT, continuous renal replacement therapy; DC, dendritic cell; ECMO, extracorporeal membrane oxygenation; IVIG, intravenous immunoglobulin; MSCs, mesenchymal stem cells; NK cells, natural killer cells; rhG-CSF, recombinant human granulocyte colony-stimulating factor; rSFIN-co, recombinant supercompound interferon; TFF2, Trefoil factor 2; vMIP, viral macrophage inflammatory protein.

[^3]: For part (B), this column indicates the intervention to prevent infection.

[^4]: Participant size as stated in registry entry.

[^5]: No literature outside trial protocol; likely tocilizumab.

[^6]: Hydrogen inhalation has shown evidence of antioxidant and anti-inflammatory effects in ischaemia--reperfusion injury.

[^7]: No literature outside trial protocol; likely a form of lung rehabilitation.

[^8]: No literature outside trial protocol; possible Janus kinase inhibitor.
